SCHEMBL16655797

SCHEMBL16655797

C=CCOc1cc2c(ccn2-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)cc1F

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 14/20 0.46
BTK Q06187 13/20 0.46
ATR Q13535 7/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16655437 0.97 PIK3CD (0.46) PIK3CDBTKATR
SCHEMBL16655382 0.95 PIK3CD (0.47) PIK3CDBTKATR
SCHEMBL16655572 0.92 PIK3CD (0.47) PIK3CDBTKATR
SCHEMBL16655856 0.88 BTK (0.39) PIK3CDBTK
SCHEMBL16655855 0.86 BTK (0.47) PIK3CDBTKATR
SCHEMBL16655568 0.85 BTK (0.39) PIK3CDBTK
SCHEMBL16655298 0.83 PIK3CD (0.60) PIK3CDBTKATR
SCHEMBL16655456 0.83 BTK (0.47) PIK3CDBTKATR
SCHEMBL23917287 0.82 SRC (0.39) PIK3CD
SCHEMBL16655591 0.81 PIK3CD (0.60) PIK3CDBTKATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US claimed
EP-3057970-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Medivation Technologies, Inc. (US) 2016-08-24 EP claimed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO claimed
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB PIK3CD 2/4885BTK 1/4885ATR 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.